We are live on ! Find out more
BDRX icon

Biodexa Pharmaceuticals
BDRX

7 hedge funds and large institutions have $48.1K invested in Biodexa Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

17% more funds holding

Funds holding: 6 → 7 (+1)

34.13% less ownership

Funds ownership: 44% → 9.88% (-34%)

99% less capital inflows, than outflows

Capital inflows: $1.67K | Capital outflows: $180K

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Caitong International Asset Management
Caitong International Asset Management
Hong Kong
+$27

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$159K
2
Armistice Capital
Armistice Capital
New York
-$15.8K
3
GAMMA Investing
GAMMA Investing
California
-$5.26K

BDRX Hedge Fund Activity: Q2 2026 in Review

7 of the 8,378 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q2 2026, worth a combined $48.1K — down 79% from $228K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new BDRX positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Caitong International Asset Management, opening a new position worth an estimated $27. The largest seller was Sabby Management, exiting entirely with an estimated $159K sold.

  • 7 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q2 2026, up from 6 in Q1 2026.
  • Funds reported $48.1K of Biodexa Pharmaceuticals stock for Q2 2026, down 79% quarter-over-quarter.
  • 2 funds opened new Biodexa Pharmaceuticals positions in Q2 2026 and 1 closed out, a net change of +1 holder.
  • The largest Biodexa Pharmaceuticals buyer in Q2 2026 was Caitong International Asset Management, an estimated $27 added.
  • The largest Biodexa Pharmaceuticals seller in Q2 2026 was Sabby Management, an estimated $159K sold.

Based on aggregated 13F filings for Q2 2026.